{"name":"Antisoma Research","slug":"antisoma-research","ticker":"","exchange":"","domain":"","description":"Antisoma Research is a biotechnology company focused on the development of novel cancer treatments. The company has a pipeline of nine drug candidates, with a focus on advancing therapies through clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AS1409","genericName":"AS1409","slug":"as1409","indication":"Other","status":"phase_1"},{"name":"Amonafide and Cytarabine","genericName":"Amonafide and Cytarabine","slug":"amonafide-and-cytarabine","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"AS1409","genericName":"AS1409","slug":"as1409","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amonafide and Cytarabine","genericName":"Amonafide and Cytarabine","slug":"amonafide-and-cytarabine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOWHdwbW0wdE5Sd1RFMElPZ2FCZW1HWmlRNDlTeFJCRkhWWlZzdzY3R3pYQVBCMWk3aXJ2bnZBNUZrNzZZcnJQSkVUU0gyMmxqd05XWldJM3Q4SGlDMUhvVThQcmdKRU9vcGYwZjkteUFDM0dpNTc1aVpoNzdCSEZ6Um1Db2JrdEZTalpTMDVOSWhDNFhCbGREOWYxaVZsaVR3SE9oZ1k2V2pscWw5NDFLMjlB?oc=5","date":"2021-01-04","type":"pipeline","source":"Fierce Biotech","summary":"Following a new trend in pharma, CRO Parexel hires its first chief patient officer - Fierce Biotech","headline":"Following a new trend in pharma, CRO Parexel hires its first chief patient officer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}